ALX Oncology Provides Update on P-II (ASPEN-06) Study of Evorpacept to Treat Gastric Cancer
Shots:
- ALX Oncology reported topline results from the P-II (ASPEN-06) study assessing evorpacept + trastuzumab, ramucirumab & paclitaxel (TRP) vs TRP alone to treat HER2+ve G/GEJ cancer patients (n=127) previously treated with anti-HER2 agent
- Study showed an ORR of 40.3% vs 26.6% with an mDoR of 15.7mos. vs 7.6mos. in the ITT population (n=127) & an ORR of 54.8% vs 23.1% in subjects with new HER2+ve biopsies (n=48). The 2EPs of PFS & OS were not mature; safety profile was well-tolerated and consistent. The data will be highlighted at future conferences
- In addition, evorpacept has been designated with FTD by the US FDA & ODD by both the EC & FDA for 2L treatment of HER2+ve G/GEJ cancer
Ref: ALX Oncology | Image: ALX Oncology
Related News:- ALX Oncology and Quantum Leap Report the First Patient Dosing of Evorpacept in the P-I Trial (I-SPY-P1-TRIAL) for Breast Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
